Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2009 1
2010 1
2011 2
2013 3
2014 2
2015 1
2016 1
2017 1
2018 2
2019 1
2020 1
2021 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, Rea D, Malaskova L, Prochazkova J, Zackova D, Voglova J, Wącław J, Cetkovsky P, Zak P, Mayer J. Racil Z, et al. Among authors: voglova j. Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31. Am J Hematol. 2018. PMID: 30054949 Free article. No abstract available.
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Zackova D, Klamova H, Belohlavkova P, Stejskal L, Necasova T, Semerad L, Weinbergerova B, Srbova D, Voglova J, Cicatkova P, Sustkova Z, Hornak T, Baranova J, Prochazkova J, Mayer J. Zackova D, et al. Among authors: voglova j. Leuk Lymphoma. 2021 Jan;62(1):194-202. doi: 10.1080/10428194.2020.1827242. Epub 2020 Oct 6. Leuk Lymphoma. 2021. PMID: 33021423
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. Hornak T, et al. Among authors: voglova j. Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317312
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J. Žáčková D, et al. Among authors: voglova j. Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12. Leukemia. 2024. PMID: 38472478 Free PMC article. No abstract available.
Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.
Pavlik T, Janousova E, Mayer J, Indrak K, Jarosova M, Klamova H, Zackova D, Voglova J, Faber E, Karas M, Machova Polakova K, Racil Z, Demeckova E, Demitrovicova L, Tothova E, Chudej J, Markuljak I, Cmunt E, Kozak T, Muzik J, Dusek L. Pavlik T, et al. Among authors: voglova j. Am J Hematol. 2013 Sep;88(9):790-7. doi: 10.1002/ajh.23508. Epub 2013 Jul 23. Am J Hematol. 2013. PMID: 23760739 Free article.
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT. Gullaksen SE, et al. Among authors: voglova j. Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18. Haematologica. 2017. PMID: 28522574 Free PMC article. Clinical Trial.
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S. Kreutzman A, et al. Among authors: voglova j. PLoS One. 2011;6(8):e23022. doi: 10.1371/journal.pone.0023022. Epub 2011 Aug 9. PLoS One. 2011. PMID: 21857985 Free PMC article.
20 results